• Clinical Insights

World Bipolar Day: Medication adherence more critical than ever

Mar 30th, 2020

Bipolar Disorder & The Pandemic

Marking World Bipolar Day to raise awareness and acceptance of bipolar disorder takes on special significance this year during the COVID-19 pandemic. Uncertainty about the disease and the social distancing required to slow its spread can deepen feelings of stress and isolation, particularly for those with mental illness. Research shows that for those living with bipolar disorder, sustained stress can have a serious negative impact.[1]

Self-care and maintaining familiar routines can ease stress and anxiety, according to the National Alliance on Mental Illness. Sticking with one’s medication regimen is also critically important, as straying from treatment can result in hospitalizations, emergency room visits and other negative outcomes. To be considered adherent, individuals must take at least 80% of their medications as prescribed. The average person living with bipolar disorder is only 41% adherent.[2]

Pharmacy Times recently published an article about the crucial role pharmacists can play in improving adherence for those living with bipolar disorder. Genoa Healthcare pharmacist Zenia Tal, PharmD, RPh said in the article, “Bipolar disorder is a lifelong condition, and I see my role in providing medication therapy management as helping empower patients to be as healthy as possible.”

Read the full article here to learn how pharmacists and medication management can play a key role in consumer care.


[1] https://www.psychologytoday.com/us/blog/bipolar-you/202003/surviving-bipolar-disorder-during-the-covid-19-pandemic

[2] Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients. J Clin Psychopharmacol. 2016;36(4):355-371. doi: 10.1097/JCP.0000000000000523.

Recent Posts


  • Behavioral Health
  • Clinical Insights
  • Treatment
Why medication-assisted treatment is essential for improving patient outcomes

1. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH. 2. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH....

  • 340B
Your questions, answered: 340B manufacturer pricing restrictions

Drug manufacturers began implementing restrictions for 340B pricing in 2020, citing alleged misuse by safety-net providers and explosive growth of the 340B Drug Pricing Program. Since then, restrictions for the...

  • Behavioral Health
  • Clinical Insights
  • Treatment
Currently available and emerging therapy options for treatment-resistant depression

Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...

  • Art Celebration
  • Consumer Stories
  • People-first Pharmacy Care
Genoa Art Celebration participant heals through art, helps others after losing daughter to substance use disorder

Content warning: This post discusses mental illness and substance use. Please call the Suicide and Crisis Lifeline at 988, the Substance Abuse and Mental Health Services Administration’s National Helpline at...